华恒生物: 兴业证券股份有限公司关于安徽华恒生物科技股份有限公司核心技术人员离职的核查意见

Core Opinion - The departure of core technical personnel, specifically Mr. Deng Jieyong, will not have a substantial impact on the company's core competitiveness and ongoing operational capabilities [3][4]. Departure Details - Mr. Deng Jieyong left the company due to personal reasons and will no longer hold any position within the company [1]. - He held 16,431 shares, representing 0.0066% of the company's total equity [2]. - During his tenure, he participated in the company's technology research and development, and all intellectual property rights related to his work belong to the company [2]. Impact on Company - The company has a total of 288 R&D personnel, accounting for 13.14% of the total workforce, indicating a well-structured R&D team [2]. - The company emphasizes that the current R&D projects are proceeding normally and that there is no single dependency on specific core technical personnel [3]. Measures Taken - Mr. Deng completed the handover of his work before leaving, ensuring that all R&D projects continue without disruption [3]. - The company plans to enhance its R&D management mechanisms and attract high-quality talent to strengthen its innovation capabilities [3]. Verification by Sponsor Institution - The sponsor institution has verified that the existing core technical personnel and R&D team can support the company's future technological development [4].